The Canadian Research and Development Pharmaceutical Sector, 2021
This study examines the contribution of the Canadian research and development (R&D) pharmaceutical sector on the Canadian economy in 2021. […]
Resources
We play an active role in breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Our team produces media releases, reports, policy papers and other informative content to keep you up to date on the most pressing issues facing our industry. Here in our resources section, you’ll find our most recent work.
ANALYSIS & REPORTS
Clinical Trials Research Note
In many areas of high unmet patient need, early access to new medicines through clinical trials are the only option for Canadian patients. There are over 3,000 ongoing clinical trials in Canada which provide significant value to patients. Early access to innovative treatments improves health outcomes, increases quality of life, and gives hope to patients and their loved ones. Clinical trials also provide value to our healthcare system, research ecosystem, and economy.
Cost Drivers Report 2023
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
RESEARCH
Bluesky Project
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022
2022 Code of Ethical Practices
Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.
INFOGRAPHICS & DATA
Two years is too long – Understanding Canada’s Drug Access Pathway
Canadians wait two years for access to new medicines through our public drug plans. That’s a full year longer than patients in most other peer countries. Two years can feel like a lifetime for a patient waiting for access to life-saving medicines or treatments.
Better Access Better Health
More than 23-million Canadians depend on access to medicines and vaccines through employer-sponsored private plans.
RELATED LINKS
Search for Specific Brand Name Drug Negotiations Status with the pCPA
Use this tool to search for brand name drugs to view their current negotiation status.
pCPA overview of the Negotiation Process
Learn more about the negotiation process from the pCPA.
Canadian Public Reimbursement Timelines
One of Innovative Medicines Canada’s guiding principles is to offer solutions to challenges in the Canadian health system. Access to new medicines is one such challenge.
Pharma 101
Use this beginner’s guide to understand the basics of how our industry works.
Advocacy
Everything you need to make an informed decision about our industry.
Newsroom
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
